Poietis
Poietis is a French biotechnology company that develops laser-assisted bioprinting platforms (NGB-R for research, NGB-C for clinical/GMP use) and the Poieskin bioprinted skin substitute, serving pharmaceutical, dermo-cosmetic, and hospital ATMP customers including BASF, L'Oréal, Servier, and AP-HM.
- Company typePrivate
- Founded2014
- HeadquartersPessac, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Poietis does
Poietis is a French biotechnology company founded in 2014 in Pessac (Bordeaux Métropole) that develops and commercializes laser-assisted bioprinting (LAB) platforms for fabricating living human tissue. Its core technology is rooted in Laser-Induced Forward Transfer (LIFT), licensed exclusively from Inserm and the University of Bordeaux, and delivers picoliter-scale, nozzle-free cell deposition with >95% post-print viability at cellular resolution (10–50 µm). The company's flagship offering is the NGB (Next Generation Bioprinting) platform, available in two versions: NGB-R for research use and NGB-C, a GMP-compliant, Class II biosafety-cabinet-integrated system for clinical manufacturing of implantable tissues. The platform combines laser, extrusion, microvalve, and UV polymerization heads on a Stäubli 6-axis robotic arm, with optional add-on modules (PickCell for image-guided spheroid pick-and-place and ViewPrint for in-line microscope-based adaptive patterning). Poietis also sells Poieskin, positioned as the first commercially available bioprinted human skin substitute.
Poietis operates a multi-revenue-stream business model: capital equipment sales (NGB-R and NGB-C bioprinters under quote-based enterprise contracts), one-time sale of bioprinted tissue products (Poieskin), licensing/royalties on its licensed Inserm/University of Bordeaux technology, and fee-for-service research collaborations. Its go-to-market combines direct enterprise sales with event-driven demand generation at TERMIS, ISBF, and Biofabrication conferences, and selective channel distribution (HVD Life Science for Austria and Germany). The company is organized to serve pharmaceutical and dermo-cosmetic R&D buyers (BASF, L'Oréal, Servier), hospital ATMP manufacturers (AP-HM Marseille — site of the world's first GMP bioprinter installation), and academic research consortia (KU Leuven Prometheus, 3d.FAB). The firm is privately held, backed by approximately €6 million in disclosed equity and non-dilutive funding, employs 30–35 people, and operates a portfolio of 70+ patents.
Poietis firmographics
Firmographics- Name
- Poietis
- Legal name
- Poietis SAS
- Website
- https://poietis.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Poietis is a French biotechnology company that develops laser-assisted bioprinting platforms (NGB-R for research, NGB-C for clinical/GMP use) and the Poieskin bioprinted skin substitute, serving pharmaceutical, dermo-cosmetic, and hospital ATMP customers including BASF, L'Oréal, Servier, and AP-HM.
- Ownership category
- akta.pro rank
Poietis industry classification
Industry- Product category
- Bioprinting Equipment and Tissue Engineering
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industries
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Poietis is headquartered
LocationHeadquarters
- HQ city
- Pessac
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Poietis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Bioprinter Sales (NGB-R and NGB-C): Sale of NGB bioprinting platforms - both research version (NGB-R) for academic and pharmaceutical R&D, and clinical version (NGB-C) for hospitals and cell therapy manufacturing centers. Revenue from capital equipment sales with typical enterprise sales cycle.
- Bioprinted Tissue Products (Poieskin): Sale of bioprinted tissue products including Poieskin, the first commercially available bioprinted human tissue. Used by pharmaceutical companies for drug testing and cosmetics companies for ingredient testing.
- Technology Licensing: Exclusive worldwide license to bioprinting technology developed at Inserm and University of Bordeaux. Technology licensing for commercial applications in tissue engineering and regenerative medicine.
- Research Partnerships and Collaborations: Fee-for-service research collaborations with pharmaceutical and cosmetic companies for development of specific tissue models, toxicology testing, and drug discovery applications.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Poietis product offering
Product offeringCore offering
Poietis designs and manufactures the NGB (Next Generation Bioprinting) robotic bioprinting platform available in two versions: NGB-R for research applications and NGB-C for clinical/GMP-compliant manufacturing of implantable tissues. The platform integrates laser-assisted bioprinting with extrusion, microvalve, and UV-curing technologies on a 6-axis robotic arm. Poietis also produces Poieskin, the first commercially available bioprinted human tissue product used for pharmaceutical testing, cosmetics evaluation, and clinical wound healing applications.
Product overview
Poietis offers a modular bioprinting platform architecture anchored by the NGB (Next Generation Bioprinting) system, available in two versions: NGB-R™ for research use and NGB-C™ for clinical/GMP manufacturing. The platform is multimodal, combining laser-assisted bioprinting (LAB) with extrusion, microvalve, and UV-curing heads on a robotic 6-axis arm, and supports add-on modules including ViewPrint™ (in-line microscope for real-time pattern adaptation) and PickCell™ (image-guided spheroid pick-and-place). The commercial tissue product Poieskin® — the first bioprinted tissue to reach the market — is produced using this technology. The portfolio spans from in vitro tissue models for pharmaceutical and dermo-cosmetic testing to implantable Advanced Therapy Medicinal Products (ATMPs) for regenerative medicine.
Differentiator
Problem solved
Functional benefit
Brands
- NGB (Next Generation Bioprinting): Multimodal bioprinting platform available in research (NGB-R) and clinical (NGB-C) versions, integrating laser, extrusion, and microvalve bioprinting technologies.
- Poieskin
- PickCell
- ViewPrint
Products and services
- NGB-R™ (Next Generation Bioprinting – Research) A robotic bioprinting platform for research applications in oncology, 3D tissue disease models, and translational research. It combines laser-assisted bioprinting (LAB) with extrusion and microvalve heads, a 6-axis robotic arm, and an in-line microscope, enabling high-precision, automated 3D tissue fabrication with cellular resolution.
- NGB-C™ (Next Generation Bioprinting – Clinical) A GMP-compliant, clinical-grade robotic bioprinting platform for manufacturing implantable bioprinted tissues in hospital ATMP manufacturing environments. It integrates laser-assisted bioprinting and extrusion technologies within a Class II Biosafety Cabinet, designed for aseptic clinical production of tissues such as skin substitutes.
- PickCell™ Module An image-guided, automated pick-and-place module for spheroid bioprinting that uses computer-vision algorithms to select spheroids based on morphology and programmatically position them to build layered or patterned tissue constructs with high reproducibility.
- ViewPrint™ Module
Quantifiable outcome
- Cell viability post-printing maintained above 95%
- +3 more outcomes
Companies that use Poietis
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Poietis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature6 records
Poietis partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- 3d.FABminorTechnology platform collaboration for evaluating NGB platform capabilities and tissue bioprinting advancements. Validation of PickCell technology integration and NGB platform compatibility with Fugu confinement systems developed by 3d.FAB for sterile bioproduction.
- HVD Life SciencecoreDistribution partnership for Poietis' NGB-R bioprinting platform in Austria and Germany. HVD Life Science provides local market access and support for tissue engineering and regenerative medicine R&D customers, bringing cutting-edge bioprinting technology to the forefront of biomedical research in these markets.
- 4-DBR (4-Deep Brain Reconstruction)coreHorizon European Innovation Council (EIC) Pathfinder Open project for revolutionizing treatment of neurodegenerative disorders. Collaborative effort to develop conceptually novel approach for brain reconstruction providing groundbreaking solution for patients with conditions having limited treatment options.
- Assistance Publique – Hôpitaux de Marseille (AP-HM)coreFirst installation of NGB bioprinting platform in hospital ATMP manufacturing area. Partnership for Phase I clinical trial of bioprinted skin substitute (Poieskin) for wound healing. AP-HM's Cell Culture and Therapy Laboratory has GMP manufacturing authorization and expertise for producing cell therapy preparations.
- Assistance Publique – Hôpitaux de Marseille (AP-HM)coreClinical research collaboration contract for Phase I clinical trial of bioprinted tissue engineering product for wound skin healing. Partnership combines Poietis' bioprinting technology with AP-HM's manufacturing authorization and clinical trial expertise in Advanced Therapy Medicinal Products.
- ServiercoreScientific partnership for 4D bioprinting of liver tissues to develop and produce liver tissues for improved detection of drug-induced liver lesions in preclinical trials. Partnership creates complex bioprinted human liver tissue containing liver cell lines and immunocompetent cells within a defined architecture imitating human liver tissue in vitro.
- Prometheus (KU Leuven)core2-year Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered ATMPs for skeletal regeneration. Combines Prometheus' cell-based technologies with Poietis' bioprinting technology to treat non-healing large cartilage and bone defects. Aims to develop automated GMP-compliant manufacturing processes for tissue implants.
- BASFcoreR&D partnership focused on refining bioprinted skin models for ingredient testing. Collaboration validated superiority of laser bioprinting for morphological accuracy and standardized signaling compared to conventional skin models in dermo-cosmetics and pharmaceutical applications.
- L'OréalcoreStrategic research partnership targeting biological complexity, specifically bioprinting of hair follicles - a major tissue engineering challenge requiring absolute precision in cellular positioning. Collaboration aims to advance understanding of skin and hair biology.
- StäublicoreStrategic partnership with Stäubli, global leader in sterile environment robotics, to power NGB platforms. TX2 6-axis robot specifically adapted for pharmaceutical use offers unsurpassed trajectory precision essential for Laser-Assisted Bioprinting technology and GMP compliance.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Poietis competitors and assessment
Company assessmentDirect peers
- BICO (formerly Cellink): Global leader in bioprinting hardware, bioinks, and lab automation. Competes directly with Poietis across research bioprinters, tissue models, and consumables for pharma/cosmetics R&D customers, but at significantly larger scale and broader product portfolio.
- Organovo: Pioneer in 3D bioprinted human tissues for preclinical research and therapeutic applications. Closely comparable technology and use cases (bioprinted liver, skin, kidney tissues), though Organovo has shifted focus away from bioprinter hardware toward disease modeling and drug discovery services.
- Aspect Biosystems: Canada-based microfluidic 3D bioprinting company developing tissue therapeutics (e.g., pancreatic tissue for diabetes). Comparable in producing high-resolution tissue constructs for clinical applications and partnering with pharma, with a similar profile of strategic alliances and Series-stage funding.
- regenHU: Swiss developer of multi-modal bioprinters (3DDiscovery) combining extrusion, inkjet, and laser-assisted heads on robotic platforms. Most direct hardware competitor to the NGB platform, targeting similar research and translational tissue engineering customers.
Emerging players
- GeSiM: German manufacturer of piezoelectric and microvalve bioprinters (BioScaffolder) and microfluidic instrumentation. Competes in the same research-tooling niche as NGB-R, particularly in European academic and pharma R&D accounts.
- Inventia Life Science: Australia-based developer of the Rastrum digital bioprinter for 3D cell culture and disease models. Comparable as a next-generation bioprinting platform focused on pharma/biology research use cases rather than implantable tissue manufacturing.
- TissUse: Berlin-based organ-on-chip company developing multi-organ microphysiological systems for drug testing. Highly comparable end-customer use case (preclinical pharma testing replacing animal models), though addressing it via microfluidic chips rather than laser-bioprinted tissue constructs.
Broad incumbents
- 3D Systems: Major industrial 3D printing incumbent with a healthcare vertical spanning surgical planning models, patient-specific implants, and bioprinting R&D. Broader portfolio and much larger installed base than Poietis, but overlapping end-customers in regenerative medicine.
- Stratasys: Global polymer 3D printing leader with healthcare applications including anatomical models and orthopedic devices. Adjacent rather than direct bioprinting competitor, but a potential broad-incumbent threat as it extends into regenerative medicine and bioprinting-adjacent workflows.
- Materialise: Belgium-based 3D printing services and software provider with deep medical vertical (personalized surgical guides, implants, anatomical models). Comparable in serving patient-specific medical manufacturing and overlapping with Poietis' hospital/clinical translation ambitions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Poietis social profiles
Digital presencePoietis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Poietis leadership team
Management profileNumber of profiles
Profiles5 records
Poietis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Poietis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Poietis
What does Poietis do?
Poietis designs and manufactures the NGB (Next Generation Bioprinting) robotic bioprinting platform available in two versions: NGB-R for research applications and NGB-C for clinical/GMP-compliant manufacturing of implantable tissues. The platform integrates laser-assisted bioprinting with extrusion, microvalve, and UV-curing technologies on a 6-axis robotic arm. Poietis also produces Poieskin, the first commercially available bioprinted human tissue product used for pharmaceutical testing, cosmetics evaluation, and clinical wound healing applications.
Is Poietis a public or private company?
Poietis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Poietis founded?
Poietis was founded in 2014. It employs 11 to 50 people.
Where is Poietis based?
Poietis is headquartered in Pessac, France, in the Europe region.
How does Poietis make money?
Four revenue lines are on record. Bioprinter Sales (NGB-R and NGB-C) is the primary driver. The others are bioprinted Tissue Products (Poieskin), technology Licensing and research Partnerships and Collaborations.
Who are Poietis's main competitors?
Direct peers on record are BICO (formerly Cellink), Organovo, Aspect Biosystems and regenHU. Emerging players are GeSiM, Inventia Life Science and TissUse. Broad incumbents are 3D Systems, Stratasys and Materialise.
Does Poietis have an API?
No public API is recorded for Poietis.
What industry is Poietis in?
Poietis's product category is Bioprinting Equipment and Tissue Engineering. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 3391 and its SIC code is 3841.